Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?
- PMID: 23962561
- DOI: 10.1016/j.canlet.2013.08.019
Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?
Abstract
Back in 1997, a suggestion to apply the concept of synthetic lethality towards the development of selective, less toxic, cancer drugs and anticancer targets, was brought forward. The availability of large scale synthetic, low-molecular-weight chemical libraries seemed to lend itself to the concept. Human/mouse genome-wide siRNAs and shRNA-expressing libraries allowing high throughput screening for target genes synergistic lethal with defined human cancer aberrations, also raised high hopes of a soon to be established selective therapy. Sixteen years later, the major experimental aspects relating to the implementation of this more focused approach to cancer drug discovery, is briefly and critically reviewed.
Keywords: Cancer therapy; Chemical synthetic lethality; Genetic synthetic lethality; Oncogenes; RNAi; Tumor suppressor genes.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
[Synthetic lethality as a functional tool in basic research and in anticancer therapy].Postepy Hig Med Dosw (Online). 2014 Sep 3;68:1091-103. doi: 10.5604/17322693.1119792. Postepy Hig Med Dosw (Online). 2014. PMID: 25228518 Review. Polish.
-
Methodological approaches in application of synthetic lethality screening towards anticancer therapy.Br J Cancer. 2009 Apr 21;100(8):1213-8. doi: 10.1038/sj.bjc.6605000. Epub 2009 Mar 24. Br J Cancer. 2009. PMID: 19319136 Free PMC article. Review.
-
The concept of synthetic lethality in the context of anticancer therapy.Nat Rev Cancer. 2005 Sep;5(9):689-98. doi: 10.1038/nrc1691. Nat Rev Cancer. 2005. PMID: 16110319 Review.
-
Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Expert Opin Biol Ther. 2016;16(2):161-72. doi: 10.1517/14712598.2016.1110141. Epub 2015 Dec 2. Expert Opin Biol Ther. 2016. PMID: 26630128 Review.
-
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.Eur J Med Chem. 2012 Mar;49:24-40. doi: 10.1016/j.ejmech.2012.01.033. Epub 2012 Jan 24. Eur J Med Chem. 2012. PMID: 22305612 Review.
Cited by
-
Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.Sci Rep. 2018 May 31;8(1):8440. doi: 10.1038/s41598-018-26783-w. Sci Rep. 2018. PMID: 29855504 Free PMC article.
-
Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.Oncotarget. 2016 Aug 23;7(34):55352-55367. doi: 10.18632/oncotarget.10536. Oncotarget. 2016. PMID: 27438146 Free PMC article.
-
AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. eCollection 2020. Am J Cancer Res. 2020. PMID: 32905466 Free PMC article.
-
Synthetic Lethal Activity of Benzophenanthridine Alkaloids From Zanthoxylum coco Against BRCA1-Deficient Cancer Cells.Front Pharmacol. 2020 Dec 3;11:593845. doi: 10.3389/fphar.2020.593845. eCollection 2020. Front Pharmacol. 2020. PMID: 33424604 Free PMC article.
-
Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.Cell Cycle. 2015;14(5):744-54. doi: 10.1080/15384101.2014.997517. Cell Cycle. 2015. PMID: 25565400 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources